Importance of circadian rhythmicity in the cholinergic treatment of Alzheimer's disease: focus on galantamine*

ABSTRACT Objective and scope: This review article used data from an extensive literature search (including MEDLINE database searches) to explore the relationships between sleep, memory and Alzheimer's disease (AD). The importance of taking into account circadian rhythmicity and acetylcholine (ACh) levels when considering acetylcholinesterase inhibitors, galantamine in particular, in the treatment of patients with AD is discussed. Review findings: Moderate changes of circadian rhythms may occur as part of the normal ageing process, but patients with AD exhibit circadian rhythm disturbances extending beyond those observed in non-demented elderly and this may lead to severe disruption of the sleep–wake cycle. Indeed, ACh plays an active role in maintaining a normal sleep pattern, which is important for memory consolidation. Low levels of ACh during slow-wave sleep compared with wakefulness have been shown to be critical for the consolidation of declarative memory. This suggests the existence of a circadian rhythm in central cholinergic transmission which modulates memory processes, with high ACh levels during wakefulness and reduced levels during slow-wave sleep. When using cholinesterase inhibitors to stimulate central cholinergic transmission in AD, respecting the natural circadian fluctuations of central cholinergic transmission may therefore be an important factor for patient improvement. Interfering with nocturnal cholinergic activity can add to memory problems and induce sleep disorders. Available data suggest that the type of cholinesterase inhibitor used and the time of administration may be critical with regard to the possible development of such disturbances. Plasma levels of galantamine, for example, are high during the waking day and lower at night, supporting a cholinergic stimulation that mirrors the physiological circadian rhythm of cholinergic activity. This may have beneficial implications with regard to sleep and memory. Conclusions: The pharmacokinetic properties of cholinesterase inhibitors may need to be taken into account to avoid interference with sleep architecture and to achieve optimum benefits from treatment on cognitive processes.

[1]  H. Kobayashi,et al.  Increase of hippocampal acetylcholine release at the onset of dark phase is suppressed in a mutant mice model of evening-type individuals , 2003, Neuroscience.

[2]  D. Giles,et al.  The effects of an orally administered cholinergic agonist on REM sleep in major depression , 2002, Biological Psychiatry.

[3]  R. Marrocco,et al.  Norepinephrine and acetylcholine mediation of the components of reflexive attention: implications for attention deficit disorders , 2004, Progress in Neurobiology.

[4]  A. Nordberg,et al.  Cholinesterase Inhibitors in the Treatment of Alzheimer’s Disease , 1998, Drug safety.

[5]  Hans Förstl,et al.  [Nightmares in patients with Alzheimer's disease caused by donepezil. Therapeutic effect depends on the time of intake]. , 2005, Der Nervenarzt.

[6]  F. Onen,et al.  [Sleep rhythm disturbances in Alzheimer's disease]. , 2003, La Revue de medecine interne.

[7]  D. Rasmusson.  The role of acetylcholine in cortical synaptic plasticity , 2000, Behavioural Brain Research.

[8]  M. Gillette,et al.  Suprachiasmatic nucleus: the brain's circadian clock. , 1999, Recent progress in hormone research.

[9]  M. Mühlethaler,et al.  Nicotinic Enhancement of the Noradrenergic Inhibition of Sleep-Promoting Neurons in the Ventrolateral Preoptic Area , 2004, The Journal of Neuroscience.

[10]  J. Hannibal,et al.  Neurotransmitters of the retino-hypothalamic tract , 2002, Cell and Tissue Research.

[11]  S. Onen.  Sommeil physiologique du sujet âgé , 2005 .

[12]  Van Someren EJ.  Circadian and sleep disturbances in the elderly. , 2000, Experimental gerontology.

[13]  J. Shua-haim,et al.  ARICEPT‐INDUCED NIGHTMARES IN ALZHEIMER'S DISEASE: 2 CASE REPORTS , 1998, Journal of the American Geriatrics Society.

[14]  Daniel J Buysse,et al.  The Pittsburgh sleep quality index: A new instrument for psychiatric practice and research , 1989, Psychiatry Research.

[15]  Joshua J Gooley,et al.  Neurobiology of the Sleep-Wake Cycle: Sleep Architecture, Circadian Regulation, and Regulatory Feedback , 2006, Journal of biological rhythms.

[16]  S. Ancoli-Israel,et al.  Acetylcholinesterase Inhibitors and Sleep Architecture in Patients with Alzheimer’s Disease , 2006, Drugs & aging.

[17]  I. McKeith,et al.  A comparison of sleep profiles in patients with dementia with Lewy bodies and Alzheimer's disease , 2000, International journal of geriatric psychiatry.

[18]  Dirk Deleu,et al.  A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. , 2001, Neurology.

[19]  J. Markowitz,et al.  Sleep-related outcomes in persons with mild to moderate Alzheimer disease in a placebo-controlled trial of galantamine. , 2003, Sleep.

[20]  H. Eisenberg,et al.  The nicotinic allosteric potentiating ligand galantamine facilitates synaptic transmission in the mammalian central nervous system. , 2002, Molecular pharmacology.

[21]  D. F. Swaab,et al.  The suprachiasmatic nucleus of the human brain in relation to sex, age and senile dementia , 1985, Brain Research.

[22]  J. Hobson,et al.  The Neurobiology of Sleep: Genetics, cellular physiology and subcortical networks , 2002, Nature Reviews Neuroscience.

[23]  B. Feige,et al.  Differential Effects of the Muscarinic M1 Receptor Agonist RS-86 and the Acetylcholine-Esterase Inhibitor Donepezil on REM Sleep Regulation in Healthy Volunteers , 2006, Neuropsychopharmacology.

[24]  C. Degueldre,et al.  Sleep after spatial learning promotes covert reorganization of brain activity. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[25]  P. Tariot,et al.  A 5-month, randomized, placebo-controlled trial of galantamine in AD , 2000, Neurology.

[26]  Donald L Bliwise,et al.  Sleep disorders in Alzheimer's disease and other dementias. , 2004, Clinical cornerstone.

[27]  M. Mirmiran,et al.  Non-pharmacological treatment of sleep and wake disturbances in aging and Alzheimer's disease: Chronobiological perspectives , 1993, Behavioural Brain Research.

[28]  G. Wilcock,et al.  Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial , 2000, BMJ : British Medical Journal.

[29]  E. Peskind,et al.  Galantamine in AD , 2000, Neurology.

[30]  G Buzsáki,et al.  The hippocampo-neocortical dialogue. , 1996, Cerebral cortex.

[31]  R. Mohs,et al.  Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group. , 1998, Archives of internal medicine.

[32]  K. Heese,et al.  Alzheimer's disease--an interactive perspective. , 2006, Current Alzheimer research.

[33]  P. Fossier,et al.  Cholinergic modulation of the cortical neuronal network , 2003, Pflügers Archiv.

[34]  S. Stahl,et al.  Examination of nighttime sleep-related problems during double-blind, placebo-controlled trials of galantamine in patients with Alzheimer's disease , 2004, Current medical research and opinion.

[35]  F. Onen,et al.  Altérations des rythmes du sommeil dans la maladie d'Alzheimer , 2003 .

[36]  J. Horiguchi,et al.  Effects of donepezil on Alzheimer's disease: The relationship between cognitive function and rapid eye movement sleep , 2004, Psychiatry and clinical neurosciences.

[37]  I. Heuser,et al.  The effect of rivastigmine on sleep in elderly healthy subjects , 2000, Experimental Gerontology.

[38]  Anna Wirz-Justice,et al.  Dawn–dusk simulation light therapy of disturbed circadian rest–activity cycles in demented elderly , 2003, Experimental Gerontology.

[39]  I. Jones,et al.  Why doesn't nicotinic ACh receptor immunoreactivity knock out? , 2005, Trends in Neurosciences.

[40]  B. Seltzer,et al.  Efficacy of donepezil in early-stage Alzheimer disease: a randomized placebo-controlled trial. , 2004, Archives of neurology.

[41]  U. Hemmeter,et al.  Effects of the Novel Acetylcholinesterase Inhibitor SDZ ENA 713 on Sleep in Man , 1993, Neuropsychopharmacology.

[42]  B. Winblad,et al.  A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD , 2001, Neurology.

[43]  A. Maelicke.  Allosteric Modulation of Nicotinic Receptors as a Treatment Strategy for Alzheimer’s Disease , 2000, Dementia and Geriatric Cognitive Disorders.

[44]  C. Pollak,et al.  Sleep Problems and Institutionalization of the Elderly , 1991, Journal of geriatric psychiatry and neurology.

[45]  Francesco Marrosu,et al.  Microdialysis measurement of cortical and hippocampal acetylcholine release during sleep-wake cycle in freely moving cats , 1995, Brain Research.

[46]  Christian Guilleminault,et al.  The effect of donepezil on sleep and REM sleep EEG in patients with Alzheimer disease: a double-blind placebo-controlled study. , 2006, Sleep.

[47]  L. Wilkins.  Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension , 2000, Neurology.

[48]  R. Mohs,et al.  A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients , 2001, Neurology.

[49]  J. D. McGaugh,et al.  Muscarinic cholinergic influences in memory consolidation , 2003, Neurobiology of Learning and Memory.

[50]  E. Someren.  Circadian and sleep disturbances in the elderly , 2000, Experimental Gerontology.

[51]  I. Heuser,et al.  Donepezil-induced REM sleep augmentation enhances memory performance in elderly, healthy persons , 2001, Experimental Gerontology.

[52]  Yasuo Hishikawa,et al.  Melatonin secretion rhythm disorders in patients with senile dementia of Alzheimer’s type with disturbed sleep–waking , 1999, Biological Psychiatry.

[53]  Rochelle E Tractenberg,et al.  The Sleep Disorders Inventory: an instrument for studies of sleep disturbance in persons with Alzheimer's disease , 2003, Journal of sleep research.

[54]  M. Hasselmo.  Neuromodulation: acetylcholine and memory consolidation , 1999, Trends in Cognitive Sciences.

[55]  A. Levey.  Muscarinic acetylcholine receptor expression in memory circuits: implications for treatment of Alzheimer disease. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[56]  R. Stickgold,et al.  Memory consolidation and reconsolidation: what is the role of sleep? , 2005, Trends in Neurosciences.

[57]  J. Rothwell.  Principles of Neural Science , 1982 .

[58]  M. Giovannini,et al.  Changes in acetylcholine extracellular levels during cognitive processes. , 2004, Learning & memory.

[59]  B. Davis,et al.  Circadian Cholinergic Rhythms: Implications for Cholinesterase Inhibitor Therapy , 2006, Dementia and Geriatric Cognitive Disorders.

[60]  F. Pasquier,et al.  Sundowning syndrome in demented patients without neuroleptic therapy. , 1996, Archives of gerontology and geriatrics.

[61]  E. Stopa,et al.  Pathologic evaluation of the human suprachiasmatic nucleus in severe dementia. , 1999, Journal of neuropathology and experimental neurology.

[62]  G. Wilcock,et al.  Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial. Galantamine International-1 Study Group. , 2000, BMJ.

[63]  E. Stopa,et al.  Circadian locomotor activity and core-body temperature rhythms in Alzheimer's disease , 1995, Neurobiology of Aging.

[64]  S. Ancoli-Israel,et al.  Effects of Galantamine Versus Donepezil on Sleep in Patients With Mild to Moderate Alzheimer Disease and Their Caregivers: A Double-Blind, Head-to-Head, Randomized Pilot Study , 2005, Alzheimer disease and associated disorders.

[65]  L. Thorpe,et al.  Assessment of Behavioural and Psychological Symptoms Associated with Dementia , 2007, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[66]  J. Turchi,et al.  Age- and Dementia-Associated Impairments in Divided Attention: Psychological Constructs, Animal Models, and Underlying Neuronal Mechanisms , 2001, Dementia and Geriatric Cognitive Disorders.

[67]  Ann C McKee,et al.  Disturbance of endogenous circadian rhythm in aging and Alzheimer disease. , 2005, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[68]  A. E. Power.  Slow-wave sleep, acetylcholine, and memory consolidation , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[69]  S. Endo,et al.  Double blind study of melatonin effects on the sleep-wake rhythm, cognitive and non-cognitive functions in Alzheimer type dementia. , 2003, Journal of Nippon Medical School = Nippon Ika Daigaku zasshi.

[70]  J. Kelsoe,et al.  Sleep electroencephalographic response to muscarinic and serotonin1A receptor probes in patients with major depression and in normal controls , 1998, Biological Psychiatry.

[71]  J. Santamaria,et al.  CSF markers in sleep neurobiology. , 2005, Clinica chimica acta; international journal of clinical chemistry.

[72]  F. Reinoso-suárez,et al.  Brain structures and mechanisms involved in the generation of REM sleep. , 2001, Sleep medicine reviews.

[73]  JA Hobson.  Sleep and dreaming , 1990 .

[74]  R. Dykes,et al.  Daily changes in the release of acetylcholine from rat primary somatosensory cortex , 1993, Brain Research.

[75]  A. McKee,et al.  Differential circadian rhythm disturbances in men with Alzheimer disease and frontotemporal degeneration. , 2001, Archives of general psychiatry.

[76]  Björn Lemmer,et al.  Chronobiology, drug-delivery, and chronotherapeutics. , 2007, Advanced drug delivery reviews.

[77]  E. Tulving.  How many memory systems are there , 1985 .

[78]  J. Born,et al.  Declarative memory consolidation: mechanisms acting during human sleep. , 2004, Learning & memory.

[79]  N Sitaram,et al.  REM sleep induction by physostigmine infusion during sleep. , 1976, Science.

[80]  J. Luxenberg,et al.  Effect of timed bright light treatment for rest‐activity disruption in institutionalized patients with Alzheimer's disease , 2005, International journal of geriatric psychiatry.

[81]  H.-J. Möller,et al.  The Effects of Donepezil in Alzheimer’s Disease – Results from a Multinational Trial1 , 1999, Dementia and Geriatric Cognitive Disorders.

[82]  R. J. McDonald,et al.  Multiple Parallel Memory Systems in the Brain of the Rat , 2002, Neurobiology of Learning and Memory.

[83]  Marc Baltzan,et al.  Sleep and aging: 1. Sleep disorders commonly found in older people , 2007, Canadian Medical Association Journal.

[84]  R. Lester,et al.  Desensitization of neuronal nicotinic receptors. , 2002, Journal of neurobiology.

[85]  P. Robert.  Understanding and Managing Behavioural Symptoms in Alzheimer's Disease and Related Dementias: Focus on Rivastigmine , 2002, Current medical research and opinion.

[86]  H. Fibiger,et al.  Cholinergic activity in the rat hippocampus, cortex and striatum correlates with locomotor activity: An in vivo microdialysis study , 1991, Pharmacology Biochemistry and Behavior.

[87]  J. Born,et al.  Low acetylcholine during slow-wave sleep is critical for declarative memory consolidation , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[88]  M. Hasselmo.  The role of acetylcholine in learning and memory , 2006, Current Opinion in Neurobiology.